SCHEMBL5422149

SCHEMBL5422149

CCCN(c1ccc(-c2ccc(OC(F)(F)F)cc2)cc1)S(=O)(=O)c1ccc(C(C)C)c(C(=O)O)c1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 3/20 0.53
TRPM8 Q7Z2W7 5/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
HTT P42858 1/20 0.49
HCRTR2 O43614 1/20 0.48
ALOX5 P09917 3/20 0.45
NR3C1 P04150 1/20 0.44
PTGES O14684 2/20 0.43
MCL1 Q07820 3/20 0.42
BCL2L1 Q07817 2/20 0.42
KEAP1 Q14145 1/20 0.42
NFE2L2 Q16236 1/20 0.42
ESR1 P03372 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376402 0.92 SERPINE1 (0.50) SERPINE1TRPM8LMNAGAAHTT
SCHEMBL4906642 0.80 HCRTR2 (0.54) SERPINE1TRPM8LMNAGAAHTT
SCHEMBL4905813 0.78 TRPM8 (0.50) TRPM8
SCHEMBL5376594 0.77 POLB (0.51) LMNA
SCHEMBL4897462 0.75 HCRTR2 (0.51) SERPINE1TRPM8LMNAGAAHTT
SCHEMBL4899886 0.74 LMNA (0.53) SERPINE1TRPM8LMNAGAAHTT
SCHEMBL4907142 0.74 HCRTR2 (0.54) SERPINE1TRPM8LMNAGAAHTT
SCHEMBL5368248 0.74 ALOX5 (0.46) SERPINE1LMNAGAAALOX5PTGES
SCHEMBL4899803 0.73 HCRTR2 (0.53) SERPINE1TRPM8LMNAGAAHTT
SCHEMBL12569956 0.72 IGF2BP2 (0.49)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP claimed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US claimed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US claimed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO claimed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
US-7262318-B2 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER, INC. (US) 2007-08-28 US disclosed
EP-1725524-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS Pfizer Products Incorporated (US) 2006-11-29 EP disclosed
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PFIZER INC 2006-11-16 US disclosed
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PFIZER INC 2005-10-13 US disclosed
WO-2005092845-A1 SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS PFIZER PRODUCTS INC. (US) 2005-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228015-A1 Substituted heteroaryl- and phenylsulfamoyl compounds PPARA, PPARG, PPARD SERPINE1 1085/4885TRPM8 4317/4885LMNA 319/4885
US-20060258723-A1 Substituted Heteroaryl- and Phenylsulfamoyl Compounds PPARG, PPARA, PPARD SERPINE1 1287/4885TRPM8 4175/4885LMNA 565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.